Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Market Has Spoken: BridgeLink Surpasses 10,000 Downloads, Solidifying Status as the Global Standard for Open-Source Health Interoperability27.1.2026 18:35:00 CET | Press release
MONTGOMERY, AL / ACCESS Newswire / January 27, 2026 / Innovar Healthcare today announced that BridgeLink, the open-source integration engine, has surpassed 10,000 enterprise downloads, a milestone that signals a decisive shift in the healthcare IT landscape. Following the market shift toward restrictive proprietary licensing for the industry's legacy engine, the healthcare community has decisively moved to BridgeLink as the premier open-source replacement. This rapid adoption-achieved in less than a year since its March 2025 launch-confirms that healthcare organizations are prioritizing strategic resilience and technical transparency over vendor lock-in. BridgeLink is no longer just an alternative; it has become the operational standard for hospitals, Digital Health, Health Information Exchanges (HIEs), and laboratories worldwide seeking to secure their interoperability infrastructure. "The volume of downloads we are seeing represents a 'Great Migration' in health tech," said Loyd Bitt
Symetrix Unveils Cognio: The Next-Generation Audio, Video, and Control Platform27.1.2026 14:15:00 CET | Press release
With breakthrough distributed architecture and wire-free design workflows, Cognio redefines how AV systems are designed, deployed, and operated; see it for the first time at ISE 2026 SEATTLE, WA / ACCESS Newswire / January 27, 2026 / Symetrix, a global leader in high-performance AV processing, control, and monitoring solutions, today announced the launch of Cognio™, a brand-new software-driven Audio, Video, and Control (AVC) ecosystem designed to dramatically simplify system design, accelerate deployment, and deliver more flexible, scalable AV experiences. Cognio will make its official public debut at Integrated Systems Europe (ISE) 2026 in Barcelona, where attendees can experience an entirely new approach to deploying Audio, Video, and Control solutions at the Symetrix booth (5M390). Cognio represents a fundamental rethinking of how AV systems are built, combining distributed intelligence with code-free control into a single platform powered by DesignOps, the patented software that un
U.S. Polo Assn. Celebrates a Landmark Debut as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz27.1.2026 13:00:00 CET | Press release
Standing Rock Claims Victory Over Flexjet in a Thrilling Final Showdown WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 27, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), celebrated its inaugural year as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz. The legendary three-day competition and record-breaking lifestyle event took place on the iconic frozen Lake St. Moritz in Switzerland's Engadin Valley and featured world-class competition, alpine elegance, fan activations, VIP experiences, and global sport celebration. More than 2,400 tons of infrastructure were installed directly onto the frozen lake of St. Moritz for this one-of-a-kind event. After two days and eight games of preliminaries, on Sunday, Jan. 25, Standing Rock prevailed over Flexjet in a close 6 - 4.5 victory.1. The intensity was high in the final Snow Polo World Cup game, with Standing Rock ultimately prevaili
AM Positions for Next Phase of Global Growth: Kelly McAndrew to Chairman; Dave Watrous to CEO27.1.2026 07:00:00 CET | Press release
AUSTIN, TX / ACCESS Newswire / January 27, 2026 / For over 21 years, Kelly McAndrew has served as Chief Executive Officer (CEO), playing a pivotal role in shaping AM Technical Solutions (AM) culture and strategic direction, enabling exceptional results. Kelly now transitions into the role of Chairman of the Board. As Chairman, Kelly will focus on investments and partnerships to further enhance the company's solution offerings. Dave Watrous will succeed Kelly as Chief Executive Officer. AM has worked closely with Dave for more than six years in the roles of customer and partner. His faith, integrity, leadership qualities, and strong industry expertise make him the ideal choice for this role. With a distinguished 30-year career in High-Technology industries, Dave brings extensive capabilities in delivering multi-billion-dollar Engineering, Procurement, Construction, Commissioning, and Validation projects worldwide. As CEO, Dave will focus on leading growth, accelerating opportunities, en
Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers26.1.2026 14:00:00 CET | Press release
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon Plc., began providing shelter and comprehensive support to women in Bamako. During this period, almost 120 women and girls have benefited from healthcare, legal aid and education. Interest in the centre remains strong, with new women continuously joining the programme. In the coming years, the initiative aims to reach several hundred vulnerable women across different regions of Mali. Why Was the House of Hope Established? The centre was created through the collaboration of Richter Gedeon Plc. (Richter), the Hungary-based Close to Africa Foundation, and the local Sini Sanuman Foundation. Its mission is to provide safety and professional support to women fleeing violence and abuse through gynaecological care, psychological and legal counselling, and educational programmes. The building was des
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom